Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease
    Mudaliar, Sunder
    Henry, Robert R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2007, 9 : S83 - S92
  • [12] Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration
    Chapman, Richard W.
    House, Aileen
    Richard, Jennifer
    Prelusky, Dan
    Lamca, James
    Wang, Peng
    Lundell, Dan
    Wu, Ping
    Ting, Pauline C.
    Lee, Joe F.
    Aslanian, Robert
    Phillips, Jonathan E.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 643 (2-3) : 274 - 281
  • [13] The treatment of obstructive lung disease in the future: role of PDE4 inhibitors
    Canonica, Giorgio Walter
    MULTIDISCIPLINARY RESPIRATORY MEDICINE, 2008, 3 (01) : 81 - 83
  • [14] Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
    Franciosi, Lui G.
    Diamant, Zuzana
    Banner, Katharine H.
    Zuiker, Rob
    Morelli, Nicoletta
    Kamerling, Ingrid M. C.
    de Kam, Marieke L.
    Burggraaf, Jacobus
    Cohen, Adam F.
    Cazzola, Mario
    Calzetta, Luigino
    Singh, Dave
    Spina, Domenico
    Walker, Michael J. A.
    Page, Clive P.
    LANCET RESPIRATORY MEDICINE, 2013, 1 (09): : 714 - 727
  • [15] Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease
    Zhu, Junliang
    Li, Xiaohui
    Zhou, Yang
    Ge, Chenglong
    Li, Xudong
    Hou, Mengying
    Wei, Yuansong
    Chen, Yongbing
    Leong, Kam W.
    Yin, Lichen
    SCIENCE ADVANCES, 2024, 10 (06)
  • [16] Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
    Tashkin, Donald P.
    Gross, Nicholas J.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 1873 - 1888
  • [18] Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
    Schett, Georg
    Sloan, Victor S.
    Stevens, Randall M.
    Schafer, Peter
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 2 (05) : 271 - 278
  • [19] The Involvement of PDE4 in the Protective Effects of Melatonin on Cigarette-Smoke-Induced Chronic Obstructive Pulmonary Disease
    Lim, Je-Oh
    Kim, Woong-Il
    Lee, Se-Jin
    Pak, So-Won
    Cho, Young-Kwon
    Kim, Jong-Choon
    Kim, Joong-Sun
    Shin, In-Sik
    MOLECULES, 2021, 26 (21):
  • [20] Pharmacological activity of difamilast, a novel PDE4 inhibitor for the topical treatment of atopic dermatitis: Comparison with other PDE4 inhibitors
    Hiyama, Hidetaka
    Arichika, Naoya
    Sakurai, Kazushi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB255 - AB255